Depemokimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Hypereosinophilic Syndrome. According to Globaldata, it is involved in 11 clinical trials, of which 2 were completed, and 9 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Depemokimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Net Present Value Model: GSK plc's Depemokimab

Buy the Model

Premium Insights

The gold standard of business intelligence.

Find out more

The revenue for Depemokimab is expected to reach an annual total of $214 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Depemokimab Overview

Depemokimab (GSK-3511294) is under development for the treatment of asthma, eosinophilic granulomatous polyangiitis, rhinosinusitis and hypereosinophilic syndrome. It is administered through subcutaneous route as a solution. The therapeutic candidate is a new biological entity (NBE). It is a long acting monoclonal antibody that acts by targeting interleukin-5.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
The company reported revenues of (British Pounds) GBP29,324 million for the fiscal year ended December 2022 (FY2022), an increase of 18.7% over FY2021. In FY2022, the company’s operating margin was 21.9%, compared to an operating margin of 17.5% in FY2021. In FY2022, the company recorded a net margin of 51%, compared to a net margin of 17.8% in FY2021. The company reported revenues of GBP8,147 million for the third quarter ended September 2023, an increase of 13.5% over the previous quarter.

For a complete picture of Depemokimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.